FDA authorizes Byetta as adjunct therapy to insulin Lantus

10/19/2011 | Wall Street Journal, The

The FDA is allowing the use of Eli Lilly and Co. and Amylin Pharmaceuticals' type 2 diabetes medicine Byetta as an add-on to Sanofi's Lantus, or insulin glargine. Byetta can be taken with or without metformin and thiazolidinedione, and in addition to diet and exercise.

View Full Article in:

Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD